Skip to content

WP-1303 Phase III long-term study

Long-term study on WP-1303 ophthalmic solution in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080224167
Enrollment
360
Registered
2018-12-03
Start date
2018-12-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanease patients with POAG, normal-tension glaucoma, exfoliation glaucoma, pigmentary glaucoma or OH

Interventions

investigational material(s) Generic name etc : WP-1303 INN of investigational material : WP-1303 Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational

Sponsors

Wakamoto pharmaceutical Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Each potential subject must satisfy all of the following criteria to be enrolled in the study. 1)Patients with POAG, normal-tension glaucoma, exfoliation glaucoma, pigmentary glaucoma or OH 2)Provision of written voluntary consent to participate in the study 3)Japanease not less than 20 years of age at informed consent 4)IOP at 9 o'clock of IOP confirmation date (-Day 14 to -Day 1) and IOP at 9 o'clock baseline (Day 0) should meet the following criteria: (1)IOP is less than 35 mmHg for both eyes (2)IOP at least one eye is not less than 15mmHg and the change from baseline IOP at IOP confirmation date is no more than 3 mmHg

Exclusion criteria

Exclusion criteria: Any potential subject who meets any of the following criteria will be excluded from participating in the study. 1)Patients who have visual acuity (corrected visual acuity if correction is necessary) of less than 0.3 in one eye at screening and baseline observation period. 2)Presence of active eye disease (eg., uveitis, ocular infection, severe dry eye). 3)Anticipated use of prohibited drugs between screening and at the completion of treatment phase. 4)Anticipated wear of contact lenses in one eye between screening and at the completion of treatment phase. 5)Presence of uncontrolled systemic disease (eg., hypertension, diabetes).

Design outcomes

Primary

MeasureTime frame
safety efficacy:intraocular pressure safety:adverse event and adverse drug reaction

Secondary

MeasureTime frame
safety efficacy efficacy:intraocular pressure safety:adverse event and adverse drug reaction

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026